LeonaBio, Inc. reported a significant increase in its net loss for the first quarter of 2026, amounting to $32.9 million, compared to a net loss of $9.1 million for the same period in 2025. This represents a 260% increase year-over-year. The company's total operating expenses also rose sharply, reaching $17.2 million, an 81% increase from $9.5 million in the prior year. The increase in expenses was primarily driven by heightened research and development costs, particularly related to the clinical development of lasofoxifene, which accounted for $8.6 million of the total R&D expenses.
In terms of financial position, LeonaBio's cash and cash equivalents decreased to $32.8 million as of March 31, 2026, down from $69.3 million at the end of 2025. The company’s total assets also fell to $71.6 million from $92.2 million, while total liabilities decreased significantly from $64.4 million to $22.3 million. This reduction in liabilities was largely due to the reclassification of the Sermonix pre-funded warrant to equity following stockholder approval in March 2026, which eliminated a significant liability from the balance sheet.
Strategically, LeonaBio has focused on advancing its drug candidates, particularly lasofoxifene for the treatment of ESR1-mutated metastatic breast cancer and ATH-1105 for amyotrophic lateral sclerosis (ALS). The company is currently conducting a Phase 3 trial for lasofoxifene and is preparing for a Phase 2 trial for ATH-1105. The acquisition of lasofoxifene in December 2025 is seen as a pivotal move to diversify the company’s pipeline and leverage its clinical development experience.
Operationally, LeonaBio has not yet generated any revenue from drug sales, as it remains in the clinical development stage. The company has raised approximately $489.8 million since its inception, primarily through equity financing. As of March 31, 2026, LeonaBio reported an accumulated deficit of $544.7 million. The company anticipates that its existing cash reserves will be sufficient to fund operations for at least the next 12 months, but it will require additional funding to support ongoing development efforts and operational costs. The outlook remains cautious, with the company acknowledging the need for substantial additional capital to continue its drug development programs.
About Athira Pharma, Inc.
Athira Pharma, Inc. is a clinical-stage biopharmaceutical company developing orally available small molecule therapeutics that modulate the neurotrophic hepatocyte growth factor (HGF) system to restore neuronal health and slow neurodegeneration. Its lead candidate, ATH-1105, targets neurodegenerative diseases like ALS by promoting neuroprotection, reducing inflammation, and enhancing nerve function. Athira leverages proprietary drug discovery, third-party manufacturing, and aims to address unmet needs in central and peripheral nervous system disorders.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.